Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the stock. Barclays reaffirmed an “equal weight” rating and set a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Mizuho cut their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. HC Wainwright reiterated a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Revance Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.96.

Revance Therapeutics Price Performance

Shares of RVNC opened at $3.09 on Friday. The stock has a market capitalization of $322.57 million, a price-to-earnings ratio of -1.60 and a beta of 0.81. The business’s 50 day simple moving average is $4.34 and its 200-day simple moving average is $4.47. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, sell-side analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional Trading of Revance Therapeutics

Several hedge funds have recently modified their holdings of RVNC. Certuity LLC purchased a new position in shares of Revance Therapeutics in the 2nd quarter worth approximately $26,000. FORA Capital LLC acquired a new stake in Revance Therapeutics in the third quarter valued at approximately $54,000. Creative Planning acquired a new stake in shares of Revance Therapeutics in the 3rd quarter worth $56,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics during the 2nd quarter worth $33,000. Finally, Accredited Investors Inc. acquired a new position in Revance Therapeutics during the 3rd quarter valued at about $67,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.